|
Printable version |
From: | "G Stolwyk" <stolwyk@wave.co.nz> |
Date: | Tue, 29 Apr 2003 18:39:08 +1200 |
A discussion took place about Pan Pharmaceutical : "A problem can occur if a Pharmaceutical is a heavy sponsor of contracts at Pan Pharmaceutical. SIG does "not" have exposure and can now produce more to replace some of that made by Pan Pharmaceuticals. But your mentioned Australian Pharmaceutical has exposure: http://www.tga.gov.au/recalls/non_panprod.htm However, MAY got hit to the tune of $15 mill. to $20 mil. as it had some contracted out to Pan Pharmaceutical. It has a liability here hence the loss. And of course others may fall in that category as well. So, I would say that the response in the pharma maket "is" consistent. Some account of some declining uptake by the public at large needs to be taken, however, given time one can expect a recovery there. Gerry "Life is either a daring adventure or nothing." |
|